Trinity Biotech (NASDAQ: TRIB) has announced the launch of its continuous glucose monitoring (CGM) microsite to provide insights into the development of its next-generation CGM biosensor technology and AI-driven health and wellness analytics platform. The site will also provide visibility on the international commercialization of these solutions.
In a statement, John Gillard, president and CEO of Trinity Biotech, said that the dedicated website for key stakeholders including potential users, payers, and physicians, will provide the design philosophy underpinning the company’s vision for this technology. “Our design and development rationale is built around the key factors of usability, affordability, and sustainability. We believe that these are fundamental factors in facilitating accessibility to this critical, important technology globally where there continues to be a very large unmet need amongst those hundreds of millions of people who are impacted by diabetes.”
Trinity Biotech is a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors.
